This is likely an incomplete or atypical presentation of NMS and requires immediate evaluation and discontinuation of Latuda.
The patient's presentation of finger rigidity and low-grade fever (99°F) after restarting lurasidone 20 mg is concerning for neuroleptic malignant syndrome, though the clinical picture is incomplete. The FDA label for Latuda explicitly warns that NMS is a potentially fatal syndrome that can occur with antipsychotic administration, characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability 1.
Clinical Assessment Algorithm
Immediately evaluate for the classic NMS tetrad:
- Hyperthermia: The patient has low-grade fever (99°F/37.2°C), which is below the typical NMS threshold of >100.4°F (38°C), but fever can be delayed or attenuated 2, 3
- Muscle rigidity: Finger stiffness is present—assess for lead pipe rigidity throughout the body, though rigidity can be minor or localized in atypical presentations 4, 5
- Altered mental status: Must assess for delirium, confusion, agitation, or decreased level of consciousness 2
- Autonomic instability: Check for tachycardia, blood pressure fluctuations, diaphoresis, pallor 2
Obtain urgent laboratory studies:
- Creatine kinase (CK) level—elevation ≥4 times upper limit of normal supports NMS 2
- Complete blood count—look for leukocytosis (15,000-30,000 cells/mm³) 2
- Comprehensive metabolic panel—assess for renal function, electrolytes, liver enzymes 2
- Rule out infectious, toxic, metabolic, or neurologic causes 2
Critical Management Decision
Discontinue Latuda immediately. The FDA label states: "If NMS is suspected, immediately discontinue LATUDA and provide intensive symptomatic treatment and monitoring" 1. This is non-negotiable even with an incomplete presentation.
Key Clinical Nuances
Atypical presentations are common and diagnostically challenging:
- NMS can present with minimal or absent rigidity 4, 5
- Fever may be delayed for hours or absent initially 3
- Low-grade fever does not exclude NMS—the syndrome exists on a spectrum 2, 4
- The recent stop-and-restart pattern is a recognized risk factor, though reintroduction doesn't always trigger recurrence 2, 6
The 20 mg dose is low but irrelevant—neither dose nor duration of exposure correlates with NMS risk 2. NMS can occur after the first dose or after dose changes 2.
Differential Diagnosis to Exclude
Before confirming NMS, rule out:
- Drug-induced Parkinsonism: Presents with rigidity and tremor but without fever or autonomic instability 2
- Acute dystonia: Typically occurs within first few doses, involves face/neck/extraocular muscles, no fever 2
- Infection: Check for pneumonia, urinary tract infection, other sources 2
- Serotonin syndrome: If patient is on SSRIs or other serotonergic agents—look for hyperreflexia, clonus, different rigidity pattern 2
Monitoring and Supportive Care
While awaiting laboratory confirmation:
- Continuous vital sign monitoring
- IV hydration to prevent rhabdomyolysis if CK is elevated 2
- External cooling measures if fever worsens 2
- Benzodiazepines for agitation if needed 2
- Consider bromocriptine or dantrolene if full NMS syndrome develops 2, 7, 8
Critical Pitfall to Avoid
Do not dismiss this presentation because the fever is "only 99°F" or because rigidity is limited to the fingers. Atypical and attenuated presentations are well-documented and can progress rapidly 2, 4, 5. The mortality rate of NMS, while decreased from 76% historically to 10-15% currently, remains significant 2. Early recognition and immediate antipsychotic discontinuation are the cornerstones of reducing morbidity and mortality 9.
If NMS is ruled out after comprehensive workup, consider alternative antipsychotic with extreme caution and close monitoring, as patients with prior NMS history have increased recurrence risk 2, 6.